Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance

[1]  Z. Zeng,et al.  LncRNA AATBC regulates Pinin to promote metastasis in nasopharyngeal carcinoma , 2020, Molecular oncology.

[2]  Z. Zeng,et al.  Epstein‐Barr virus‐encoded miR‐BART6‐3p inhibits cancer cell proliferation through the LOC553103‐STMN1 axis , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  Z. Zeng,et al.  Intestinal Flora and Disease Mutually Shape the Regional Immune System in the Intestinal Tract , 2020, Frontiers in Immunology.

[4]  Z. Zeng,et al.  Gossypol induces apoptosis of multiple myeloma cells through the JUN-JNK pathway. , 2020, American journal of cancer research.

[5]  R. Deberardinis.  Tumor Microenvironment, Metabolism, and Immunotherapy. , 2020, The New England journal of medicine.

[6]  M. Zhou,et al.  Abnormal X chromosome inactivation and tumor development , 2020, Cellular and Molecular Life Sciences.

[7]  Z. Zeng,et al.  Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy , 2020, Molecular Cancer.

[8]  P. Hegde,et al.  Top 10 Challenges in Cancer Immunotherapy. , 2020, Immunity.

[9]  Z. Zeng,et al.  The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer , 2020, Journal of Cancer.

[10]  Reem Saleh,et al.  Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. , 2020, Seminars in cancer biology.

[11]  J. Powell,et al.  Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion , 2019, Science.

[12]  B. Jiang,et al.  PTEN Suppresses Glycolysis by Dephosphorylating and Inhibiting Autophosphorylated PGK1. , 2019, Molecular cell.

[13]  R. Lang,et al.  Targeting L-Lactate Metabolism to Overcome Resistance to Immune Therapy of Melanoma and Other Tumor Entities , 2019, Journal of oncology.

[14]  W. Sellers,et al.  Metabolomic adaptations and correlates of survival to immune checkpoint blockade , 2019, Nature Communications.

[15]  G. Calin,et al.  GLS2 is protumorigenic in breast cancers , 2019, Oncogene.

[16]  G. Berchem,et al.  Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints. , 2019, Cancer letters.

[17]  Z. Zeng,et al.  Neoantigen vaccine: an emerging tumor immunotherapy , 2019, Molecular Cancer.

[18]  Jason W Locasale,et al.  Metabolic landscape of the tumor microenvironment at single cell resolution , 2019, Nature Communications.

[19]  R. Deberardinis,et al.  MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer , 2019, Genes & development.

[20]  Junling Liu,et al.  Acylglycerol Kinase Maintains Metabolic State and Immune Responses of CD8+ T Cells. , 2019, Cell metabolism.

[21]  T. Sandoval,et al.  Dendritic Cell Metabolism and Function in Tumors. , 2019, Trends in immunology.

[22]  Yanni Peng,et al.  Glutamine Synthetase Promotes Radiation Resistance via Facilitating Nucleotide Metabolism and Subsequent DNA Damage Repair. , 2019, Cell reports.

[23]  Z. Zeng,et al.  TSC22D2 identified as a candidate susceptibility gene of multi-cancer pedigree using genome-wide linkage analysis and whole exome sequencing. , 2019, Carcinogenesis.

[24]  Z. Zeng,et al.  Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis , 2019, Cellular and Molecular Life Sciences.

[25]  Z. Zeng,et al.  PVT1 Promotes Cancer Progression via MicroRNAs , 2019, Front. Oncol..

[26]  P. Romero,et al.  Navigating metabolic pathways to enhance antitumour immunity and immunotherapy , 2019, Nature Reviews Clinical Oncology.

[27]  Z. Zeng,et al.  GPC6 Promotes Cell Proliferation, Migration, and Invasion in Nasopharyngeal Carcinoma , 2019, Journal of Cancer.

[28]  Guizhong Zhang,et al.  Lipid Metabolic Pathways Confer the Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Tumor , 2019, Front. Immunol..

[29]  Z. Zeng,et al.  The role of Wnt signaling pathway in tumor metabolic reprogramming , 2019, Journal of Cancer.

[30]  M. Turner,et al.  Membrane Cholesterol Efflux Drives Tumor-Associated Macrophage Reprogramming and Tumor Progression. , 2019, Cell metabolism.

[31]  B. Eynde.  Faculty Opinions recommendation of Fatty acid transport protein 2 reprograms neutrophils in cancer. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[32]  Z. Zeng,et al.  Proteomic Analysis of the Molecular Mechanism of Lovastatin Inhibiting the Growth of Nasopharyngeal Carcinoma Cells , 2019, Journal of Cancer.

[33]  A. Roussel,et al.  Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. , 2019, Cell reports.

[34]  E. Fuchs,et al.  Adaptive Immune Resistance Emerges from Tumor-Initiating Stem Cells , 2019, Cell.

[35]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[36]  A. Villani,et al.  Targeting the CBM complex causes Treg cells to prime tumors for immune checkpoint therapy , 2019, Nature.

[37]  D. Sancho,et al.  Metabolic Control of Dendritic Cell Functions: Digesting Information , 2019, Front. Immunol..

[38]  Haiyang Xie,et al.  Blocking Triggering Receptor Expressed on Myeloid Cells‐1‐Positive Tumor‐Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti‐Programmed Cell Death Ligand 1 Resistance in Liver Cancer , 2019, Hepatology.

[39]  D. Allard,et al.  Targeting the adenosine pathway for cancer immunotherapy. , 2019, Seminars in immunology.

[40]  F. Su,et al.  Extracellular vesicle-packaged HIF-1α-stabilizing lncRNA from tumour-associated macrophages regulates aerobic glycolysis of breast cancer cells , 2019, Nature Cell Biology.

[41]  Z. Zeng,et al.  Upregulation and hypomethylation of lncRNA AFAP1‑AS1 predicts a poor prognosis and promotes the migration and invasion of cervical cancer. , 2019, Oncology reports.

[42]  J. Locasale,et al.  T cell stemness and dysfunction in tumors are triggered by a common mechanism , 2019, Science.

[43]  J. Welsh,et al.  Altered cancer metabolism in mechanisms of immunotherapy resistance , 2019, Pharmacology & therapeutics.

[44]  Z. Zeng,et al.  Natural killer group 2D receptor and its ligands in cancer immune escape , 2019, Molecular Cancer.

[45]  Mingwei Liu,et al.  Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma , 2019, Nature.

[46]  B. Faubert,et al.  Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity , 2019, Nature.

[47]  E. Giannoni,et al.  Lactate: A Metabolic Driver in the Tumour Landscape. , 2019, Trends in biochemical sciences.

[48]  A. Laurence,et al.  Lactate inhibits ATP6V0d2 expression in tumor-associated macrophages to promote HIF-2&agr;–mediated tumor progression , 2019, The Journal of clinical investigation.

[49]  F. Di Virgilio,et al.  The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment , 2019, Oncogene.

[50]  M. Zhou,et al.  Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape , 2019, Molecular Cancer.

[51]  Robert Lesurf,et al.  Molecular landmarks of tumor hypoxia across cancer types , 2019, Nature Genetics.

[52]  F. Castro-Giner,et al.  Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding , 2019, Cell.

[53]  M. Stojak,et al.  Alterations in arginine and energy metabolism, structural and signalling lipids in metastatic breast cancer in mice detected in plasma by targeted metabolomics and lipidomics , 2018, Breast Cancer Research.

[54]  J. Locasale,et al.  Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism , 2018, Cell.

[55]  K. Vousden,et al.  A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3 , 2018, Cell metabolism.

[56]  Stephen T. C. Wong,et al.  Systems biology–based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma , 2018, Science Translational Medicine.

[57]  Xionglei He,et al.  Biosynthetic energy cost for amino acids decreases in cancer evolution , 2018, Nature Communications.

[58]  Lieping Chen,et al.  A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization , 2018, Cell.

[59]  Zena Werb,et al.  Roles of the immune system in cancer: from tumor initiation to metastatic progression , 2018, Genes & development.

[60]  J. T. Afshari,et al.  Macrophage plasticity, polarization, and function in health and disease , 2018, Journal of cellular physiology.

[61]  A. Hotson,et al.  A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models , 2018, Cancer Immunology Research.

[62]  V. Boussiotis,et al.  Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy , 2018, Front. Oncol..

[63]  T. Shlomi,et al.  Transfer of miRNA in Macrophage-Derived Exosomes Induces Drug Resistance in Pancreatic Adenocarcinoma. , 2018, Cancer research.

[64]  F. He,et al.  Monoacylglycerol lipase regulates cannabinoid receptor 2-dependent macrophage activation and cancer progression , 2018, Nature Communications.

[65]  Guohui Li,et al.  Macrophage-Associated PGK1 Phosphorylation Promotes Aerobic Glycolysis and Tumorigenesis. , 2018, Molecular cell.

[66]  Soong-Hyun Kim,et al.  Recent Development of Small Molecule Glutaminase Inhibitors. , 2018, Current topics in medicinal chemistry.

[67]  E. Meylan,et al.  Glucose transporters in cancer – from tumor cells to the tumor microenvironment , 2018, The FEBS journal.

[68]  M. Yi,et al.  Emerging role of lipid metabolism alterations in Cancer stem cells , 2018, Journal of Experimental & Clinical Cancer Research.

[69]  A. Sandler,et al.  Recent progress in therapeutic antibodies for cancer immunotherapy. , 2018, Current opinion in chemical biology.

[70]  Haiyan Tan,et al.  Hippo/Mst signalling couples metabolic state and immune function of CD8α+ dendritic cells , 2018, Nature.

[71]  R. Davis,et al.  Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. , 2018, Cell metabolism.

[72]  Asher Mullard.  IDO takes a blow , 2018, Nature Reviews Drug Discovery.

[73]  Z. Zeng,et al.  Role of metabolism in cancer cell radioresistance and radiosensitization methods , 2018, Journal of Experimental & Clinical Cancer Research.

[74]  D. M. Smith,et al.  Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis , 2018, Immunity.

[75]  J. Wargo,et al.  The gut microbiota influences anticancer immunosurveillance and general health , 2018, Nature Reviews Clinical Oncology.

[76]  S. Ostrand-Rosenberg.  Myeloid derived-suppressor cells: their role in cancer and obesity. , 2018, Current opinion in immunology.

[77]  Chenqi Xu,et al.  Regulation of T cell signalling by membrane lipids , 2018, Nature Reviews Immunology.

[78]  Z. Zeng,et al.  Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities , 2018, Molecular Cancer.

[79]  R. White,et al.  As Extracellular Glutamine Levels Decline, Asparagine Becomes an Essential Amino Acid. , 2018, Cell metabolism.

[80]  M. Netea,et al.  Metabolic changes in tumor cells and tumor-associated macrophages: A mutual relationship. , 2018, Cancer letters.

[81]  Laurence Zitvogel,et al.  Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.

[82]  E. Le Chatelier,et al.  Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.

[83]  Riyue Bao,et al.  The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients , 2018, Science.

[84]  K. Flaherty,et al.  Mechanisms of resistance to immune checkpoint inhibitors , 2018, British Journal of Cancer.

[85]  Gianmarco Rinaldi,et al.  Metabolic interactions in cancer: cellular metabolism at the interface between the microenvironment, the cancer cell phenotype and the epigenetic landscape , 2018, Wiley interdisciplinary reviews. Systems biology and medicine.

[86]  G. Qing,et al.  Oncogenic MYC Activates a Feedforward Regulatory Loop Promoting Essential Amino Acid Metabolism and Tumorigenesis. , 2017, Cell reports.

[87]  G. Burnstock,et al.  The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression , 2017, Purinergic Signalling.

[88]  A. Sewell,et al.  Metabolic Adaptation of Human CD4+ and CD8+ T-Cells to T-Cell Receptor-Mediated Stimulation , 2017, Front. Immunol..

[89]  J. Liu,et al.  Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor , 2017, Nature Immunology.

[90]  G. Freeman,et al.  Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. , 2017, Cancer cell.

[91]  A. Iyer,et al.  PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..

[92]  Liqin Zheng,et al.  Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells , 2017, Oncoimmunology.

[93]  Wei-Lin Jin,et al.  Reprogramming of the Tumor in the Hypoxic Niche: The Emerging Concept and Associated Therapeutic Strategies. , 2017, Trends in pharmacological sciences.

[94]  Gerald C. Chu,et al.  Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism , 2017, Nature Communications.

[95]  N. Agarwal,et al.  The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. , 2017, Immunotherapy.

[96]  H. Yang,et al.  Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells , 2017, Oncogene.

[97]  Michel Sadelain,et al.  Therapeutic T cell engineering , 2017, Nature.

[98]  C. Thompson,et al.  Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine , 2017, The EMBO journal.

[99]  R. Geffers,et al.  Hypoxia Enhances Immunosuppression by Inhibiting CD4+ Effector T Cell Function and Promoting Treg Activity , 2017, Cellular Physiology and Biochemistry.

[100]  G. Koehl,et al.  Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment , 2017, Front. Immunol..

[101]  M. Bower,et al.  INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology , 2017, ACS medicinal chemistry letters.

[102]  Wei Xiong,et al.  Role of tumor microenvironment in tumorigenesis , 2017, Journal of Cancer.

[103]  G. Hotamışlıgil.  Inflammation, metaflammation and immunometabolic disorders , 2017, Nature.

[104]  S. Chouaib,et al.  Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer , 2017, Oncogene.

[105]  Cheng Chang,et al.  Comprehensive Proteomics Analysis Reveals Metabolic Reprogramming of Tumor-Associated Macrophages Stimulated by the Tumor Microenvironment. , 2017, Journal of proteome research.

[106]  S. Sakaguchi,et al.  Regulatory T cells in cancer immunotherapy , 2016, Cell Research.

[107]  S. Haferkamp,et al.  LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. , 2016, Cell metabolism.

[108]  K. Gardner,et al.  Targeting renal cell carcinoma with a HIF-2 antagonist , 2016, Nature.

[109]  Asher Mullard.  Cancer metabolism pipeline breaks new ground , 2016, Nature Reviews Drug Discovery.

[110]  S. Crowe,et al.  Regulators of Glucose Metabolism in CD4+ and CD8+ T Cells , 2016, International reviews of immunology.

[111]  A. Schulze,et al.  The multifaceted roles of fatty acid synthesis in cancer , 2016, Nature Reviews Cancer.

[112]  Jiangqi Liu,et al.  High expression of CD39 in gastric cancer reduces patient outcome following radical resection. , 2016, Oncology letters.

[113]  D. Fukumura,et al.  Arginine dependence of tumor cells: targeting a chink in cancer’s armor , 2016, Oncogene.

[114]  W. Linehan,et al.  Ionic immune suppression within the tumour microenvironment limits T cell effector function , 2016, Nature.

[115]  Sathesh Bhat,et al.  Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small cell lung cancer in preclinical models , 2016, Nature Medicine.

[116]  Bram Boeckx,et al.  Tumor hypoxia causes DNA hypermethylation by reducing TET activity , 2016, Nature.

[117]  V. Boussiotis,et al.  Clinical significance of T cell metabolic reprogramming in cancer , 2016, Clinical and Translational Medicine.

[118]  S. Påhlman,et al.  Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. , 2016, Pharmacology & therapeutics.

[119]  H. Harada.  Hypoxia-inducible factor 1–mediated characteristic features of cancer cells for tumor radioresistance , 2016, Journal of radiation research.

[120]  Navdeep S. Chandel,et al.  Fundamentals of cancer metabolism , 2016, Science Advances.

[121]  Wei Yang,et al.  Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism , 2016, Nature.

[122]  A. Ohta.  A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment , 2016, Front. Immunol..

[123]  Chuanzhao Zhang,et al.  Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA , 2016, Proceedings of the National Academy of Sciences.

[124]  D. Munn,et al.  IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. , 2016, Trends in immunology.

[125]  D. Gabrilovich,et al.  The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. , 2016, Trends in immunology.

[126]  C. Thompson,et al.  The Emerging Hallmarks of Cancer Metabolism. , 2016, Cell metabolism.

[127]  E. Mills,et al.  Reprogramming mitochondrial metabolism in macrophages as an anti‐inflammatory signal , 2016, European journal of immunology.

[128]  S. Varambally,et al.  Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction , 2015, Nature Immunology.

[129]  E. Buchbinder,et al.  CTLA-4 and PD-1 Pathways , 2016, American Journal of Clinical Oncology.

[130]  Chi V. Dang,et al.  From Krebs to clinic: glutamine metabolism to cancer therapy , 2016, Nature Reviews Cancer.

[131]  Young-sil Yoon,et al.  CREB pathway links PGE2 signaling with macrophage polarization , 2015, Proceedings of the National Academy of Sciences.

[132]  A. Azmi,et al.  Immune evasion in cancer: Mechanistic basis and therapeutic strategies. , 2015, Seminars in cancer biology.

[133]  Jason B. Williams,et al.  Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.

[134]  F. Ginhoux,et al.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.

[135]  F. Giles,et al.  Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy , 2015, Clinical Cancer Research.

[136]  S. Biswas.  Metabolic Reprogramming of Immune Cells in Cancer Progression. , 2015, Immunity.

[137]  J. Locasale,et al.  Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses , 2015, Cell.

[138]  R. Schreiber,et al.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression , 2015, Cell.

[139]  D. Munn,et al.  514 Results of Phase 1b trial of the Indoleamine 2,3-dioxygenase (IDO) Pathway Inhibitor Indoximod plus Ipilimumab for the treatment of unresectable stage III or IV melanoma , 2015 .

[140]  W. Langridge,et al.  The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity , 2015, Vaccines.

[141]  M. Merad,et al.  Cancer: A dendritic-cell brake on antitumour immunity , 2015, Nature.

[142]  F. D’Acquisto,et al.  Lactate Regulates Metabolic and Pro-inflammatory Circuits in Control of T Cell Migration and Effector Functions , 2015, PLoS biology.

[143]  Juan R. Cubillos-Ruiz,et al.  ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis , 2015, Cell.

[144]  W. Zou,et al.  Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies , 2015, Cancer Immunology Research.

[145]  J. Rathmell,et al.  T cell metabolic fitness in antitumor immunity. , 2015, Trends in immunology.

[146]  R. Deberardinis,et al.  Metabolic pathways promoting cancer cell survival and growth , 2015, Nature Cell Biology.

[147]  Jeffrey W. Smith,et al.  Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. , 2015, Cancer cell.

[148]  Elena De Marchi,et al.  Emerging roles of P2X receptors in cancer. , 2015, Current medicinal chemistry.

[149]  L. Walker,et al.  Confusing signals: Recent progress in CTLA-4 biology , 2015, Trends in immunology.

[150]  T. Sparwasser,et al.  Fatty acid metabolism in the regulation of T cell function. , 2015, Trends in immunology.

[151]  Jian Ye,et al.  Controlling T cell senescence in the tumor microenvironment for tumor immunotherapy , 2015, Oncoimmunology.

[152]  P. Thevenot,et al.  l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. , 2015, Cancer research.

[153]  A. Harris,et al.  Acetyl-CoA Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress , 2015, Cancer cell.

[154]  Matias Ostrowski,et al.  Glucose Metabolism Regulates T Cell Activation, Differentiation, and Functions , 2014, Front. Immunol..

[155]  S. Ostrand-Rosenberg,et al.  Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. , 2015, Advances in cancer research.

[156]  B. Oronsky,et al.  Follow the ATP: tumor energy production: a perspective. , 2014, Anti-cancer agents in medicinal chemistry.

[157]  I. Müller,et al.  Metabolism via Arginase or Nitric Oxide Synthase: Two Competing Arginine Pathways in Macrophages , 2014, Front. Immunol..

[158]  Yan Su,et al.  Gangliosides drive the tumor infiltration and function of myeloid-derived suppressor cells. , 2014, Cancer research.

[159]  Yanping Zhang,et al.  TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence , 2014, EMBO molecular medicine.

[160]  J. Rathmell,et al.  Metabolic Reprogramming towards Aerobic Glycolysis Correlates with Greater Proliferative Ability and Resistance to Metabolic Inhibition in CD8 versus CD4 T Cells , 2014, PloS one.

[161]  J. Rathmell,et al.  The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. , 2014, Cell metabolism.

[162]  Siok-Keen Tey.  Adoptive T-cell therapy: adverse events and safety switches , 2014, Clinical & translational immunology.

[163]  P. Dessen,et al.  PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation , 2014, The Journal of experimental medicine.

[164]  Mong-Hong Lee,et al.  Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies , 2014, Cancer biology & medicine.

[165]  R. Sun,et al.  Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. , 2014, Cell metabolism.

[166]  M. C. Archer,et al.  Fatty acid synthase plays a role in cancer metabolism beyond providing fatty acids for phospholipid synthesis or sustaining elevations in glycolytic activity. , 2014, Experimental cell research.

[167]  Taofeek K Owonikoko,et al.  Altered glutamine metabolism and therapeutic opportunities for lung cancer. , 2014, Clinical lung cancer.

[168]  J. Geschwind,et al.  Tumor glycolysis as a target for cancer therapy: progress and prospects , 2013, Molecular Cancer.

[169]  Chih-Hao Chang,et al.  Fueling Immunity: Insights into Metabolism and Lymphocyte Function , 2013, Science.

[170]  Ralph J DeBerardinis,et al.  Glutamine and cancer: cell biology, physiology, and clinical opportunities. , 2013, The Journal of clinical investigation.

[171]  Robert V Farese,et al.  Cellular fatty acid metabolism and cancer. , 2013, Cell metabolism.

[172]  Peter Vogel,et al.  mTORC1 couples immune signals and metabolic programming to establish Treg cell function , 2013, Nature.

[173]  B. Faubert,et al.  Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis , 2013, Cell.

[174]  R. Giridhar,et al.  ACAT inhibitors: the search for novel cholesterol lowering agents. , 2013, Mini reviews in medicinal chemistry.

[175]  E. Pearce,et al.  Metabolic pathways in immune cell activation and quiescence. , 2013, Immunity.

[176]  John M. Asara,et al.  Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway , 2013, Nature.

[177]  Yigong Shi,et al.  A proposed role for glutamine in cancer cell growth through acid resistance , 2013, Cell Research.

[178]  Katrin F Chua,et al.  Cancer: Metabolism in 'the driver's seat , 2012, Nature.

[179]  W. Wick,et al.  Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. , 2012, Cancer research.

[180]  J. Bussink,et al.  Targeting Hypoxia, HIF-1, and Tumor Glucose Metabolism to Improve Radiotherapy Efficacy , 2012, Clinical Cancer Research.

[181]  E. Clambey,et al.  Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function , 2012, Immunologic Research.

[182]  P. Rodriguez,et al.  Metabolism of L-Arginine by Myeloid-Derived Suppressor Cells in Cancer: Mechanisms of T cell suppression and Therapeutic Perspectives , 2012, Immunological investigations.

[183]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[184]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[185]  P. Kalinski.  Regulation of Immune Responses by Prostaglandin E2 , 2012, The Journal of Immunology.

[186]  J. Ricci,et al.  Cancer metabolism: current perspectives and future directions , 2012, Cell Death and Disease.

[187]  C. Dang,et al.  Otto Warburg's contributions to current concepts of cancer metabolism , 2011, Nature Reviews Cancer.

[188]  Lin Zhang,et al.  Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells , 2011, Nature.

[189]  E John Wherry,et al.  T cell exhaustion , 2011 .

[190]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[191]  A. Levine,et al.  The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes , 2010, Science.

[192]  A. Mantovani,et al.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.

[193]  M. Smyth,et al.  Extracellular adenosine triphosphate and adenosine in cancer , 2010, Oncogene.

[194]  J. Fechner,et al.  An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells , 2010, The Journal of Immunology.

[195]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[196]  Erika L. Pearce.  Metabolism in T cell activation and differentiation. , 2010, Current opinion in immunology.

[197]  K. Vousden,et al.  The role of p53 in glucose metabolism. , 2010, Current opinion in cell biology.

[198]  R. Deberardinis,et al.  Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer , 2010, Oncogene.

[199]  P. Oefner,et al.  Lactic Acid and Acidification Inhibit TNF Secretion and Glycolysis of Human Monocytes , 2009, The Journal of Immunology.

[200]  P. Worley,et al.  The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. , 2009, Immunity.

[201]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[202]  R. Ahmed,et al.  mTOR regulates memory CD8 T cell differentiation , 2009, Nature.

[203]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[204]  P. Rodriguez,et al.  Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives , 2008, Immunological reviews.

[205]  M Hiraoka,et al.  Significance of HIF-1-active cells in angiogenesis and radioresistance , 2007, Oncogene.

[206]  J. Menéndez,et al.  Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis , 2007, Nature Reviews Cancer.

[207]  Gregor Rothe,et al.  Inhibitory effect of tumor cell-derived lactic acid on human T cells. , 2007, Blood.

[208]  D. Munn,et al.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance. , 2007, The Journal of clinical investigation.

[209]  J. Flier,et al.  TLR4 links innate immunity and fatty acid-induced insulin resistance. , 2006, The Journal of clinical investigation.

[210]  A. Ohta,et al.  A2A adenosine receptor protects tumors from antitumor T cells , 2006, Proceedings of the National Academy of Sciences.

[211]  H. Pelicano,et al.  Glycolysis inhibition for anticancer treatment , 2006, Oncogene.

[212]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[213]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[214]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[215]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[216]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[217]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[218]  C. Dang,et al.  Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc* , 2000, The Journal of Biological Chemistry.

[219]  E. Rofstad,et al.  High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. , 2000, Cancer research.

[220]  M. Kuwano,et al.  Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. , 2000, International journal of cancer.

[221]  G. Zhu,et al.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.

[222]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[223]  M. Guppy,et al.  Glucose is essential for proliferation and the glycolytic enzyme induction that provokes a transition to glycolytic energy production. , 1994, The Journal of biological chemistry.

[224]  M. R. Schinitsky.  Active immunotherapy for cancer. , 1973, Lancet.

[225]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.